Searchable abstracts of presentations at key conferences in endocrinology

ea0081p661 | Pituitary and Neuroendocrinology | ECE2022

Metyrapone vs osilodrostat in the short-term therapy of endogenous Cushing’s syndrome: results from a retrospective single center analysis

Detomas Mario , Altieri Barbara , Deutschbein Timo , Fassnacht Martin , Dischinger Ulrich

Background: Although surgery is considered the first-line treatment for patients with endogenous Cushing’s syndrome (CS), medical therapy is often required to control severe hypercortisolism. Metyrapone and osilodrostat are inhibitors of 11β-hydroxylase that have not been directly compared yet.Methods: Retrospective analysis of patients with adrenocorticotropin (ACTH)-dependent and ACTH-independent CS treated with metyrapone or osilodrostat (as...

ea0073aep826 | Late Breaking | ECE2021

The promising role of Agouti related peptide in the differentiation of ACTH-independent Cushing syndrome

Detomas Mario , Altieri Barbara , Fassnacht Martin , Dischinger Ulrich

BackgroundAgouti related peptide (AgRP) is a neuropeptide, produced by the hypothalamus and by the adrenal glands. AgRP is an antagonist of proopiomelanocortin (POMC) and its principal role is to stimulate appetite. Although current evidences suggest that AgRP levels are influenced by glucocorticoids, it is still not clear, whether they depend on adrenocorticotropic hormone (ACTH) or cortisol. One of the aims of this study was to address this issue. Furt...

ea0090oc9.4 | Oral Communications 9: Adrenal and Cardiovascular Endocrinology 2 | ECE2023

Recovery of adrenal function after stopping mitotane in patients with adrenocortical carcinoma

Altieri Barbara , Kimpel Otilia , Megerle Felix , Detomas Mario , Chifu Irina , Quinkler Marcus , Matthias Kroiss , Fassnacht Martin

Background: Mitotane is regularly used in patients with adrenocortical carcinoma (ACC) adjuvantly, in patients with high risk of recurrence, and in advanced disease. Multiple effects of mitotane result in adrenal insufficiency in virtually all patients. However, it is unclear how frequently the hypothalamic-pituitary-adrenal (HPA) axis is recovering after treatment discontinuation. Here, we aim to investigate the HPA axis after treatment with mitotane.Me...

ea0035p535 | Endocrine tumours and neoplasia | ECE2014

Expression of inhibitor of apoptosis protein BIRC7/livin in adrenocortical tumors

Altieri Barbara , Sbiera Silviu , Steinhauer Sonja , Fassnacht Martin , Allolio Bruno , Ronchi Cristina L

Introduction: Adrenocortical tumors consist in frequent benign adenomas (ACA) and rare highly malignant carcinomas (ACC). BIRC7/livin gene, a member of the inhibitors of apoptosis family, plays an important role in tumorigenesis in a variety of malignancies. Different studies demonstrated that BIRC7 overexpression represent a risk factor for cancer development and progression. The aim of our study was to evaluate the expression of BIRC7 in normal adrenals and adrenocortical tu...

ea0070aep622 | Pituitary and Neuroendocrinology | ECE2020

Sporadic neuroendocrine neoplasms in young-adult patients: Differences in natural history, prognosis and treatment compared to adult-elderly patients

Altieri Barbara , Modica Roberta , Bottiglieri Filomena , de Cicco Federica , Faggiano Antongiulio , Colao Annamaria

Introduction: Sporadic neuroendocrine neoplasms (NEN) occur rarely in young-adult (YA) patients, with an estimated incidence is about 2.8 cases per million, and data specific to their epidemiology are limited. The aim of our study was to better characterize the natural history, prognosis and management of NEN in YA patients (≤ 35 years old) compared to adult-elderly (AE; >35 years old).Methods: A retrospective observational study including 204 ...

ea0032p23 | Adrenal cortex | ECE2013

Immunohistochemical markers of adrenal cortical tumors

Altieri Barbara , Fadda Guido , Capozzi Anna , Pontecorvi Alfredo , Casa Silvia Della

Introduction: Adrenocortical tumors (ACTs) are usually divided in adenoma (ACA) or carcinoma (ACC) according to histopathologic methods. Some lesions are occasionally difficult to classify according to these criteria. We studied the use of some immunohistochemical markers to recognise the difference between malignant and benign tumors.Materials and methods: We studied 12 patients affected by ACC and 10 by ACA. Clinical evaluation and hormone analysis wer...

ea0081p385 | Endocrine-Related Cancer | ECE2022

PD-1 and PD-L1 immune checkpoint expression - the prognostic impact on adrenocortical carcinoma

Landwehr Laura-Sophie , Sbiera Iuliu , Altieri Barbara , Remde Hanna , Kircher Stefan , Sbiera Silviu , Kroiss Matthias , Fassnacht Martin

Adrenocortical carcinoma (ACC) is a very severe endocrine malignancy with poor prognosis. While cancer immunotherapies have revolutionized the treatment of several cancer entities, the results of initial studies of different immune checkpoint inhibitors in ACC were heterogeneous and clinically substantial responses were observed only in a subset of patients. Expression of immune checkpoint molecules - programmed cell death 1 (PD-1) and its ligand PD-L1 - has been shown to pred...

ea0081p153 | Pituitary and Neuroendocrinology | ECE2022

Subtype-specific pattern of white blood cell differential in endogenous Cushing’s syndrome

Detomas Mario , Altieri Barbara , Chifu Irina , Remde Hanna , Landwehr Laura-Sophie , Sbiera Silviu , Kroiss Matthias , Fassnacht Martin , Deutschbein Timo

Objective: Glucocorticoid excess impairs immune function, thereby predisposing patients with endogenous Cushing’s syndrome (CS) to infections. However, it is still not clear whether there is a CS-subtype specific pattern in white blood cell (WBC) and WBC differential (WBCD) count.Methods: Retrospective monocentric cohort study in patients with either overt endogenous CS or adrenal adenomas with autonomous cortisol secretion (ACS), with WBC and WBCD ...

ea0086p9 | Adrenal and Cardiovascular | SFEBES2022

Inflammation-Based Scores as Predictors of Treatment Response in Advanced Adrenocortical Carcinoma

Mangone Alessandra , S. Elhassan Yasir , Prete Alessandro , Asia Miriam , Detomas Mario , Altieri Barbara , Mantovani Giovanna , Ronchi Cristina L.

Background: Standard treatment for advanced adrenocortical carcinoma (ACC) is mitotane in monotherapy or combined with etoposide, doxorubicin and cisplatin (EDP), yet biomarkers predictive of treatment response are lacking. Inflammation-based scores were proposed as predictors for gemcitabine+capecitabine efficacy, used as second-line in progressive ACC. We investigated the role of inflammation-based scores in predicting response to first-line treatment in advanced ACC.<p ...

ea0090oc6.6 | Oral Communications 6: Endocrine-related Cancer | ECE2023

Cellular landscape of adrenocortical carcinomas determined by molecular profiling of primary, recurrent and metastatic tumour samples at single-nuclei resolution.

Altieri Barbara , S. Tourigny David , Secener Ali Kerim , Sbiera Silviu , Arampatzi Panagiota , Sauer Sascha , Fassnacht Martin , Ronchi Cristina

Background: Molecular mechanisms of malignant adrenocortical tumorigenesis remain elusive despite previous comprehensive genomic studies. Nonetheless, cellular heterogeneity of primary, recurrent and metastatic adrenocortical carcinoma (ACC) haven’t been fully investigated.Aim: To characterize the molecular profile of different cell subtypes in primary, recurrent and metastatic ACC by single-nuclei RNA sequencing (snRNA-Seq), using adult human norma...